Welcome back. Pancake spent most of last week dragging a glucose meter test strip around the apartment after I dropped one. Gigi watched. Roger ignored both of them. I mention this because the lead story this week is about a device that could change the lives of every diabetic cat and dog whose owners have ever wrestled with a finger prick equivalent at 6 a.m. Here is what crossed our desk this week.

That is the question ALR Technologies SG (OTC: ALRTF) is betting it can answer in the second quarter of this year. The company confirmed last week, in coverage from dvm360, that it will relaunch the GluCurve Pet CGM in the United States this quarter through Covetrus, the country's largest veterinary distributor. Canada got it first, in January. Now it is the U.S. veterinary channel's turn.

If the name is new to you, here is the elevator version. GluCurve is described as the first and only veterinary-specific continuous glucose monitor for cats and dogs. The sensor reads glucose every three minutes and stays on the animal for up to 14 days. Application is meant to be a one-button affair with an adhesive pad, designed to spare the patient and the owner the worst of the spot-check ritual. Data flows from the sensor to the ALRT Veterinary Web Portal, which is what veterinarians actually use to dose insulin and look at trends.

A quote from Joe Stern, head of animal health at ALR Technologies, is doing the work in most of this week's coverage. He said you cannot prick the finger of a cat or dog the way you would a person, and even when you can draw blood from the ear, paw, or vein, a single reading does not give you the data you need to dose insulin properly or see trends. Stern also said the company has fielded enormous interest from veterinarians, pet owners, and animal health companies because there is what he called a desperate need for a holistic product to manage diabetic pets. You can read the original company announcement on the ALR Technologies investor page, with a PRNewswire mirror for the full press text.

The market case is genuinely large. ALR cites diabetes prevalence of roughly 1 in 175 cats and 1 in 300 dogs. Stern's stated demand estimate, which we are reporting as his estimate and not an audited figure, is up to 300,000 units per year in Canada, 3 million units per year in the United States, and 3 million units per year in Europe. Manufacturing is happening with CGM Medical Technology Shenzhen at a Foxconn facility. The product page lives at glucurve.com, with patient-education material at glucurve.com/aboutdiabetes.

Here is where Tech4Pets has to slow down and read the marketing carefully.

The company has stated, in its own materials, that the GluCurve sensor delivers accuracy comparable to the gold-standard veterinary blood glucose meter. That claim, as written, is based on internal testing. It has not yet appeared in a peer-reviewed venue. ALR has also said it scheduled an independent non-inferiority study comparing the GluCurve to a gold-standard veterinary BGM. That study reportedly began last December. The result, as far as we can find, is not yet public. Until it is, every clinician should treat the accuracy claim as pending validation rather than confirmed.

This is not a knock on the device. It is a knock on the press cycle around the device. The same dvm360 piece notes that competitor Adapet currently ships a 9-day device and is working to extend it to 14 days, per Dustin Brietzke, the company's director of operations. So the category is real, the engineering challenges are real, and the demand is real. None of that substitutes for published data.

Why is this our scoop? Three reasons.

First, the diabetic patient population in companion animal medicine has been chronically underserved by the kind of continuous monitoring that completely changed the standard of care in human endocrinology. A device that genuinely works for two weeks at a time, with a friendly application process, would be a meaningful clinical tool. We want it to work.

Second, the distribution model is unusually clean. Selling exclusively through Covetrus is a strategic choice that puts the device in front of the veterinarians who write the prescriptions and own the relationship with diabetic pet owners. That tightens the feedback loop and creates a more credible adoption pathway than a direct-to-consumer launch.

Third, and most important for what this newsletter cares about, the GluCurve story is a near-perfect test case for how vendors should communicate accuracy and how the veterinary press should report it. A press release that says "comparable to the gold standard" without published numbers is not the same as a peer-reviewed sensitivity, specificity, and accuracy table. Both can be true. Only one is verifiable today.

So what should clinicians do with this in May? Three concrete things, none of which require a verdict on the device.

One. If you have diabetic feline or canine patients whose owners are running into the wall of intermittent BGM checks, ask Covetrus when the product will land in your market and request the company's internal accuracy data in writing. You are entitled to see it.

Two. Build a short list of patients you would consider for an early trial when the product ships. Diabetic remission monitoring in cats is a strong candidate use case because trend data over 14 days arguably matters more there than at any other point in clinical management.

Three. Watch for the independent non-inferiority results. When they are published, send us the citation. We will cover them. If they confirm the company's accuracy claims, this device deserves rapid adoption. If they do not, the same press cycle that ran this week will need to run a correction.

The headline question stays open. What does it take to make a CGM your cat will actually wear? In a few months we should have a much better answer.

Bionet launches the O'Pet Curv wireless ICU monitor. dvm360 covered the launch on April 27, with the original Bionet announcement available at GlobeNewswire and product specs on bionetus.com. The device weighs 18 grams, runs 40 hours on a battery charge, captures ECG, heart rate, respiratory rate, and temperature, and supports up to six patients per receiver via Bluetooth and cloud. It is IP68 waterproof. Auto-saved alarm events include a 60 second clip with 20 seconds of pre-event data. Jacqueline Lopez, Director of Sales at Bionet's Animal Health Division, said veterinary teams can now track patient vitals from anywhere in the clinic or remotely, which she framed as a workflow optimization for busy practices. The pitch reads as plausible. Anyone who has ever tried to read a postoperative ECG over a barking ward knows the appeal of remote vitals.

Covetrus adds AI features to its Pulse veterinary operating system. dvm360 reported on April 23 that the cloud-based vOS now includes AI-powered visit summaries, SOAP note generation, and AI-suggested next-best actions. Covetrus claims the package saves up to five minutes per appointment, which translates into roughly an extra hour of practitioner time per day. Quotes come from Scot Gillespie, chief product and technology officer at Covetrus, and Link Welborn, DVM, the company's chief veterinary officer. Editorial caveat: AI scribe products have a track record of impressive demos and uneven real-world performance, particularly with breed names, drug names, and dosing strings. Five minutes per visit is a meaningful claim worth measuring against your own clinic data.

Golden Child launches a premium DTC dog food brand with $37 million. TechCrunch's Connie Loizos reported on April 27 that Hilary Coles, a co-founder of Hims and Hers, has teamed up with the Atomic startup studio and design partner Lacornerie to launch Golden Child. The line includes a fresh frozen meal subscription at roughly $3 per day and a shelf-stable liquid topper at $19.95 per bottle. Atomic developed the concept using its painted-door testing methodology and an analysis of 11,000 fresh dog food reviews. The story matters less for the food itself, which is one more entrant in a crowded fresh category, and more for the founder pattern. Consumer wellness operators are now treating premium pet nutrition as the next obvious adjacency, with the same playbook that built Hims, Glossier, and Olipop.

Capstone Partners flags a delayed but improving consumer M&A market. Capstone's annual consumer M&A report landed April 27 and includes the pet sector among the 14 categories tracked. Headline figures: median EV/EBITDA across the sample sits at 9.2x, a 10 year low. Large transactions above $250 million reached 30.6 percent of disclosed deal value, which the report frames as an early precursor to a broader rebound. About 27.4 percent of advisors surveyed expect 2026 multiples to rise. Quote from Ken Wasik, Head of Investment Banking at Capstone. For pet brands considering a raise or a sale this year, the takeaway is that buyers exist and large strategic checks are getting written, but the small-and-mid-cap multiple compression has not fully unwound.

According to PubMed, Murakami and colleagues at Purdue University, working with Vetology Innovations, published an accuracy investigation of AI-based detection of urothelial carcinoma in canine abdominal radiographs in Veterinary Radiology and Ultrasound (May 2026, 67(3):e70172). The convolutional neural network was trained on 500 ultrasound-confirmed UC studies and 500 controls, then validated on 185 UC and 180 control studies. Reported sensitivity was 69 percent, specificity 67 percent, and overall accuracy 68 percent. The model performed better on more severe UC presentations with mineralization, and the ventrodorsal view outperformed the lateral view in this dataset, which the authors flag as worth further work. Bridge to this week's scoop: where GluCurve's manufacturers describe accuracy comparable to a gold-standard BGM based on internal testing alone, Murakami's team published their actual sensitivity, specificity, and accuracy numbers in a peer-reviewed venue with appropriate hedging. That is the bar GluCurve's pending non-inferiority study will be measured against.

According to PubMed, Tripathy and colleagues at Texas A&M's Department of Biomedical Engineering and the Department of Small Animal Clinical Sciences, in collaboration with Ulster University, published a cross-species cardiac troponin I biosensor study in Small (Wiley) on February 26, 2026, 22(20):e12096. The platform combines an MP-locked aptamer with a multimeric DNAzyme-coupled hyperbranched hybridization chain reaction, and reaches a detection limit of 0.25 nanograms per liter in 25 to 30 minutes using only 25 microliters of serum. Cross-species validation reported 90.91 percent accuracy and 89.89 percent recall on human samples and 83.33 percent accuracy and 85.71 percent recall on canine samples, supported by a machine learning framework with three hyperparameter optimization strategies. The headline implication is the same direction GluCurve is pointing: the next wave of veterinary point-of-care devices is going to look a lot like cross-species adaptations of human-grade biosensors, with their accuracy reported the way Tripathy reported it.

Halo Collar 5. Now $524 retail at halocollar.com, down from $599 after the March 2026 price reduction. The device is co-founded by Cesar Millan and Ken Ehrman and ships with AlwaysOn dual-frequency L1 and L5 GPS, 48 hour battery life, AI-assisted signal processing, virtual fence creation, real-time tracking, and training feedback. Pack Membership runs $9.99 to $19.99 per month across the Bronze, Silver, and Gold tiers. The price drop is the operative news here. Multi-frequency GPS at this price point is an unusual value proposition, particularly for owners of dogs who range across mixed urban and rural environments where single-frequency trackers tend to drift.

Whisker Litter-Robot 5 Pro. $899 at whisker.com, launched October 2025 alongside the Litter-Robot 5 ($799) and the more compact Litter-Robot EVO ($599). The Pro adds two AI-powered cameras: a forward-facing unit that uses facial recognition to distinguish individual cats in multi-cat households, and an interior litter-bed camera. WasteID technology automatically distinguishes urine from feces to power smarter cycle timing and odor control. SmartScale tracks weight changes that can flag health issues early. Whisker has stated it is investing more than $50 million in engineering and R&D between 2025 and 2026. Editorial note: the multi-cat identification feature is the most interesting part for clinicians who work with feline-specific behavioral or urinary cases, since the data layer it produces is exactly what owners typically cannot give you reliably.

FDA expands New World screwworm Emergency Use Authorization to companion bird species, AVMA News, April 24, 2026. Coverage of the expanded EUA for companion animal applications, including pet birds.

Seven digital veterinary technology trends shaping practices in 2026, IDEXX Software. A practice-management lens on the same workflow shifts the Covetrus Pulse story above is touching.

Gallant partners with MWI on cold-chain stem cell distribution, Today's Veterinary Business, March 3, 2026. Distribution-side news for veterinary regenerative medicine that is worth pairing with the Covetrus distribution story above.

Funded startups working to pamper pets, Crunchbase News. A useful sweep of recent pet startup funding patterns for anyone tracking the next round of category entrants.

If GluCurve's U.S. relaunch lands as expected this quarter, will you adopt a CGM for your diabetic patients in the next 12 months, or wait for the independent non-inferiority data? Respond in the comments.

Thanks for reading. If this issue was useful, share it with one veterinarian, one product manager, or one engineer who would care.

Forwarded this from a friend? That is like sniffing the food bowl after someone else got there first. Subscribe to Bytes & Barks and get the fresh stuff in your inbox every weekend.